Edwards Lifesciences
1,258 hedge funds and large institutions have $38.9B invested in Edwards Lifesciences in 2025 Q3 according to their latest regulatory filings, with 112 funds opening new positions, 446 increasing their positions, 445 reducing their positions, and 105 closing their positions.
7% more first-time investments, than exits
New positions opened: 112 | Existing positions closed: 105
0% more repeat investments, than reductions
Existing positions increased: 446 | Existing positions reduced: 445
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
0% less funds holding
Funds holding: 1,264 → 1,258 (-6)
0.53% less ownership
Funds ownership: 85.68% → 85.16% (-0.53%)
5% less capital inflows, than outflows
Capital inflows: $3.32B | Capital outflows: $3.48B
13% less call options, than puts
Call options by funds: $295M | Put options by funds: $337M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$942M |
| 2 |
UBS AM
Chicago,
Illinois
|
+$321M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$240M |
| 4 |
Jennison Associates
New York
|
+$179M |
| 5 |
Bank of New York Mellon
New York
|
+$111M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$664M |
| 2 |
Millennium Management
New York
|
-$383M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$260M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$180M |
| 5 |
JP Morgan Chase
New York
|
-$134M |
EW Hedge Fund Activity: Q3 2025 in Review
1,258 of the 7,659 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q3 2025, worth a combined $38.9B — down 1% from $39.3B a quarter earlier.
Buyers outnumbered sellers: 112 funds opened new EW positions and 105 closed out — a net gain of 7 holders — while 446 added to existing stakes and 445 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $942M. The largest seller was Citadel Advisors, cutting an estimated $664M.
- 1,258 institutional investors held Edwards Lifesciences (EW) as of Q3 2025, down from 1,264 in Q2 2025.
- Funds reported $38.9B of Edwards Lifesciences stock for Q3 2025, down 1% quarter-over-quarter.
- 112 funds opened new Edwards Lifesciences positions in Q3 2025 and 105 closed out, a net change of +7 holders.
- The largest Edwards Lifesciences buyer in Q3 2025 was Fidelity Investments, an estimated $942M added.
- The largest Edwards Lifesciences seller in Q3 2025 was Citadel Advisors, an estimated $664M sold.
Based on aggregated 13F filings for Q3 2025.